← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recent progress of JAK inhibitors for hematological disorders. (2023/09/01) ♡
• [Impact of immunosuppression intensified conditioning regimen for patients with strong positive pre-transplantation donor-specific anti-HLA antibodies (DSAs) undergoing haploidentical hematopoietic stem cell transplantation]. (2023/08/14) ♡
• Acute myelofibrosis superseding B-lymphoblastic leukemia/lymphoma. (2023/08/08) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates. (2023/08/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis. (2023/08/01) ♡
• JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. (2023/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bomedemstat as an investigative treatment for myeloproliferative neoplasms. (2023/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis. (2023/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The emerging importance of immunophilins in fibrosis development. (2023/06/01) ♡
• Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. (2023/04/27) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Langerhans cell histiocytosis associated with primary myelofibrosis presenting as disseminated maculopapular rash. (2023/04/01) ♡
• Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (2023/04/01) ♡
• Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver. (2023/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Refractory thrombocytopenia and myelofibrosis in a novel KDSR mutation: Case report and literature review. (2023/04/01) ♡
• ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. (2023/03/15) ♡
• Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation. (2023/03/01) ♡
• Myelofibrosis progression grading based on type I and type III collagen and fibrillin 1 expression boosted by whole slide image analysis. (2023/03/01) ♡
• Leukocytosis and MPNs: Where do we stand? (2023/03/01) ♡
• Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival. (2023/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report. (2023/02/23) ♡
• A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2. (2023/02/01) ♡
• Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. (2023/02/01) ♡
• JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options. (2023/02/01) ♡
• Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. (2023/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. (2023/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Biological drivers of clinical phenotype in myelofibrosis. (2023/02/01) ♡
• Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. (2023/02/01) ♡
• Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms. (2023/02/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. (2023/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment? (2023/02/01) ♡
• A Diagnostic Impact of Serum Autotaxin Levels in Patients with Bone Marrow Fibrosis. (2023/02/01) ♡
• Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells. (2023/01/05) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Enigma portal: Peritoneal effusion in a patient with a myeloproliferative neoplasm. (2023/01/01) ♡
• Haploidentical Hematopoietic Cell Transplantation for Myelofibrosis in the Ruxolitinib Era. (2023/01/01) ♡
• Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. (2023/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. A Co-Management Model for Myeloid Malignancies That Evolved during the COVID-19 Pandemic. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical and clinicopathological features and outcomes of cats with suspected dietary induced pancytopenia. (2023/01/01) ♡
• [Development of novel therapeutic agents for myelofibrosis]. (2023/01/01) ♡
• [Allogeneic hematopoietic cell transplantation for myeloproliferative neoplasms]. (2023/01/01) ♡
• Clinico-pathological profile of patients with plasma cell neoplasms with special reference to bone marrow fibrosis and amyloid deposition. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Characteristics of myelodysplastic syndromes with der(1;7)(q10;p10)]. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A New Blood Score for Myelofibrosis Staging (2023-12-20) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia (2023-12-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis (2023-12-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (2023-12-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). (2023-11-24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) (2023-11-14) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.